Own CSL shares? Here's what's in the development pipeline

Research into messenger RNA (mRNA) has ramped up since the onset of COVID-19.

| More on:
Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have gained 7% since the S&P/ASX 200 Index (ASX: XJO) listed biotech share held its annual research and development (R&D) briefing on 19 October.

Below, we take a look at what's in that pipeline.

What is the ASX 200 biotech company developing?

As the Motley Fool reported on the day, CSL invested more than US$1 billion (AU$1.35 billion) into R&D in the 2021 financial year. That money supported 6 therapeutic areas, 4 scientific platforms, and 2 businesses.

Breaking those down, the 6 therapeutic areas are:

  • Immunology,
  • Hematology,
  • Respiratory,
  • Cardiovascular and metabolic,
  • Transplant, and
  • Influenza

The 4 scientific platforms are:

  • Plasma fractionation,
  • Recombinant technology,
  • Cell and gene therapy, and
  • Vaccines

And the 2 businesses are:

  • CSL Behring, and
  • Seqirus

Among the highlights, CSL announced that its Seqirus business was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services.

The multi-year contract centres around CSL's adjuvanted, cell-based seasonal influenza vaccine (aQIVc) and next-generation self-amplifying mRNA for seasonal and pandemic influenza (sa-mRNA). CSL intends to develop 2 influenza A(H2Nx) vaccine candidates for assessment in a Phase 1 clinical study. The end goal is to help communities stay safe in the event of an influenza pandemic.

CSL also announced a new collaboration with the Walter and Eliza Hall Institute for Medical Research in Australia to create a Centre for Biologic Therapies.

Commenting on that collaboration and what it means for CSL's development pipeline, CSL's Senior Vice President Andrew Nash said:

CSL's antibody library will be the engine room of biologics discovery at the Centre and, importantly, the knowledge transfer between the two organizations and the utilization of shared assets, resources, and facilities will be of great value.

This expansion of our relationship with WEHI will help ensure that the long-term investment of public funds into medical research in Australia is translated into both a benefit for patients and the Australian economy.

How have CSL shares been performing?

CSL shares have been on a bit of a rollercoaster over the past 12 months. It's a ride that has left them 3% in the green. By comparison, the ASX 200 has gained 17% over the same period.

Over the past month, CSL shares are up 8%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »